Gottlieb AB, et al. - Experts evaluated the impact of brodalumab on lesional symptoms using the psoriasis symptom inventory (PSI), a validated patient-reported instrument. They randomized the patients to receive brodalumab (140 or 210 mg every 2 weeks [Q2W]), placebo (AMAGINE-1/-2/-3), or ustekinumab (AMAGINE-2/-3) during a 12-week induction phase, followed by a maintenance phase through week 52. Compared to placebo and ustekinumab, rapid, robust improvements in symptoms assessed by the PSI, including itch were noted with brodalumab.